Current status and future direction of cancer research using artificial intelligence for clinical application.

Journal: Cancer science
PMID:

Abstract

The expectations for artificial intelligence (AI) technology have increased considerably in recent years, mainly due to the emergence of deep learning. At present, AI technology is being used for various purposes and has brought about change in society. In particular, the rapid development of generative AI technology, exemplified by ChatGPT, has amplified the societal impact of AI. The medical field is no exception, with a wide range of AI technologies being introduced for basic and applied research. Further, AI-equipped software as a medical device (AI-SaMD) is also being approved by regulatory bodies. Combined with the advent of big data, data-driven research utilizing AI is actively pursued. Nevertheless, while AI technology has great potential, it also presents many challenges that require careful consideration. In this review, we introduce the current status of AI-based cancer research, especially from the perspective of clinical application, and discuss the associated challenges and future directions, with the aim of helping to promote cancer research that utilizes effective AI technology.

Authors

  • Ryuji Hamamoto
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, Tokyo, Japan.
  • Masaaki Komatsu
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Masayoshi Yamada
    Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan. masyamad@ncc.go.jp.
  • Kazuma Kobayashi
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute.
  • Masamichi Takahashi
    Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo, 104-0045, Japan.
  • Mototaka Miyake
    Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo 104-0045, Japan.
  • Shunichi Jinnai
    Department of Dermatologic Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Takafumi Koyama
    Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.
  • Nobuji Kouno
    Department of Surgery, Graduate School of Medicine, Kyoto University.
  • Hidenori Machino
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Satoshi Takahashi
    Department of Neurosurgery, University of Tokyo, Tokyo.
  • Ken Asada
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Naonori Ueda
    Disaster Resilience Science Team, RIKEN Center for Advanced Intelligence Project, Tokyo, Japan.
  • Syuzo Kaneko
    Division of Molecular Modification and Cancer Biology, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.